XML 53 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1

Organization and Summary of Significant Accounting Policies (Narrative) (Details)		12 Months Ended			35 Months Ended
	Dec. 30, 2017 USD ($)	Dec. 28, 2018 USD ($) segment product	Dec. 29, 2017 USD ($)	Dec. 30, 2016 USD ($)	Dec. 28, 2018 USD ($)
Organization And Summary Of Significant Policies [Line Items]
Number of products that entered in the commercial marketplace | product		4
Number of operating segments | segment		1
Increase in net cash provided by investing activities		$ (297,850,000)	$ 36,795,000	$ (214,548,000)
Accumulated deficit	$ 1,570,433,000	$ 880,363,000	1,829,172,000		$ 880,363,000
Number of reportable segments | segment		1
Impairment charge on goodwill		$ 0	0	0
Percent discount for prompt payment		2.00%
Discount expected to be earned		100.00%
Inventory expensed as research and development, not capitalized as inventory		$ 0			0
Collaborative Arrangement with Ipsen
Organization And Summary Of Significant Policies [Line Items]
Milestone payments earned		$ 140,000,000			$ 275,000,000
Collaborative Arrangement with Ipsen | Collaborative Arrangement with GlaxoSmithKline
Organization And Summary Of Significant Policies [Line Items]
Percent of royalty on net sale		3.00%
ASU 2016-18
Organization And Summary Of Significant Policies [Line Items]
Increase in net cash provided by investing activities			$ 1,000,000	$ 1,500,000
ASU 2014-09 | Adjustments Due to the Adoption of Topic 606
Organization And Summary Of Significant Policies [Line Items]
Accumulated deficit	(258,505,000)
ASU 2014-09 | Adjustments Due to the Adoption of Topic 606 | Collaborative Arrangement with Ipsen | EMA Filing Acceptance - HCC
Organization And Summary Of Significant Policies [Line Items]
Milestone payments earned	10,000,000
ASU 2016-02 | Restatement
Organization And Summary Of Significant Policies [Line Items]
Accumulated deficit	$ (234,000)
Commercial Presence in Markets Worldwide
Organization And Summary Of Significant Policies [Line Items]
Number of products that entered in the commercial marketplace | product		3
Products Derived from Cabozantinib
Organization And Summary Of Significant Policies [Line Items]
Number of products that entered in the commercial marketplace | product		2

X

- Definition

Inventory, Manufactured Before Regulatory Approval

+ References

No definition available.

+ Details

Name:	exel_InventoryManufacturedBeforeRegulatoryApproval
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Milestone Payments Earned

+ References

No definition available.

+ Details

Name:	exel_MilestonePaymentsEarned
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Number of Products in Commercial Market

+ References

No definition available.

+ Details

Name:	exel_NumberofProductsinCommercialMarket
Namespace Prefix:	exel_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Organization And Summary Of Significant Policies [Line Items]

+ References

No definition available.

+ Details

Name:	exel_OrganizationAndSummaryOfSignificantPoliciesLineItems
Namespace Prefix:	exel_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percent of royalty on net sale.

+ References

No definition available.

+ Details

Name:	exel_PercentOfRoyaltyOnNetSale
Namespace Prefix:	exel_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Sales Revenue, Discount Expected to be Earned, Percent

+ References

No definition available.

+ Details

Name:	exel_SalesRevenueDiscountExpectedtobeEarnedPercent
Namespace Prefix:	exel_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Sales Revenue, Percent Discount for Prompt Payment

+ References

No definition available.

+ Details

Name:	exel_SalesRevenuePercentDiscountForPromptPayment
Namespace Prefix:	exel_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266

+ Details

Name:	us-gaap_GoodwillImpairmentLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

+ Details

Name:	us-gaap_NetCashProvidedByUsedInInvestingActivities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.

+ References

No definition available.

+ Details

Name:	us-gaap_NumberOfOperatingSegments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.

+ References

No definition available.

+ Details

Name:	us-gaap_NumberOfReportableSegments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

+ Details

Name:	us-gaap_RetainedEarningsAccumulatedDeficit
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201618Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	exel_MilestoneObjectiveAxis=exel_EMAFilingAcceptanceHCCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RestatementAxis=srt_RestatementAdjustmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=exel_CommercialPresenceInMarketsWorldwideMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=exel_ProductsDerivedfromCabozantinibMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: